Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

ClinicalTrials.gov ID: NCT01428063

Public ClinicalTrials.gov record NCT01428063. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Re-Treatment Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to provide anti-hepatitis C virus drugs to patients who received placebo + peginterferon alfa-2a + ribavirin in prior Bristol-Myers Squibb (BMS) studies and determine whether addition of these drugs results in higher cure rates in patients who previously failed therapy. Approximately 100 genotype 1b patients who received placebo in BMS study NCT01428063 (AI447-028) will receive active drugs in this study.

Study identification

NCT ID
NCT01428063
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
276 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2011
Primary completion
Aug 31, 2014
Completion
Nov 30, 2014
Last update posted
May 26, 2016

2011 – 2014

United States locations

U.S. sites
20
U.S. states
16
U.S. cities
20
Facility City State ZIP Site status
Baptist Medical Center South Montgomery Alabama 36116
Scripps Clinic La Jolla California 92037
Scpmg/ Kaiser Permanente Los Angeles Medical Center Los Angeles California 90027
University Of Colorado Denver And Hospital Aurora Colorado 80045
Yale University School Of Medicine New Haven Connecticut 06520
Uf Hepatology Research At Ctrb Gainesville Florida 32610
Schiff Center For Liver Diseases Miami Florida 33136
Mercy Medical Center Baltimore Maryland 21202
Digestive Disease Associates, P.A. Catonsville Maryland 21228
Henry Ford Health System Detroit Michigan 48202
Washington University School Of Medicine St Louis Missouri 63110
North Shore Long Island Jewish Health System Manhasset New York 11030
Duke University Medical Center Durham North Carolina 27710
Options Health Research, Llc Tulsa Oklahoma 74104
University Of Pennsylvania Philadelphia Pennsylvania 19104
Nashville Medical Research Institute Nashville Tennessee 37205
Baylor College Of Medicine Houston Texas 77030
Alamo Medical Research San Antonio Texas 78215
Metropolitan Research Fairfax Virginia 22031
Dean Clinic Madison Wisconsin 53715

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01428063, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 26, 2016 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01428063 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →